{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:22:35Z","timestamp":1773300155326,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.urolonc.2020.09.017","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T09:01:29Z","timestamp":1603443689000},"page":"195.e7-195.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non\u2013muscle-invasive bladder cancer after BCG failure"],"prefix":"10.1016","volume":"39","author":[{"given":"Rodolfo","family":"Hurle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Casale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Morenghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Saita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2maria","family":"Buffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lughezzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiuseppe","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Frego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Paciotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Guazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2020.09.017_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0002","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2020.09.017_bib0003","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00345-018-2591-1","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.017_bib0004","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/JU.0000000000000297","article-title":"Emerging immunotherapy options for bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer","volume":"202","author":"Meng","year":"2019","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.017_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bju.14065","article-title":"The impact of the global bacille Calmette-Gu\u00e9rin shortage on treatment patterns: population-based data","volume":"121","author":"Perera","year":"2018","journal-title":"S. BJU Int."},{"key":"10.1016\/j.urolonc.2020.09.017_bib0006","first-page":"1","article-title":"Robotic versus open radical cystectomy throughout the learning phase: insights from a real-life multicenter study","author":"Lenfant","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0007","article-title":"Robotic versus open radical cystectomy for bladder cancer in adults","author":"Rai","year":"2019","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2020.09.017_bib0008","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bju.14643","article-title":"Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease","volume":"123","author":"Doyle","year":"2019","journal-title":"BJU Int"},{"issue":"17","key":"10.1016\/j.urolonc.2020.09.017_bib0009","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.017_bib0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cncr.26238","article-title":"Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder","volume":"118","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.017_bib0011","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.017_bib0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Gu\u00e9rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"Porena","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.28","article-title":"Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study","author":"Hurle","year":"2020","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0014","series-title":"Textbook of bladder cancer","article-title":"Bladder cancer: diagnosis and clinical management","year":"2006"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0015","series-title":"Common terminology criteria for adverse events. Version 4.03","year":"2010"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0016","unstructured":"EAU guidelines on non-muscle invasive bladder cancer; athttps:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0017","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0018","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol."},{"issue":"75","key":"10.1016\/j.urolonc.2020.09.017_bib0019","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0020","unstructured":"A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) therapy. CliniclaTrial.Gov:NCT02625961"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000919","article-title":"A Phase 1 trial of intravesical cabazitaxel, gemcitabine, and cisplatin for the treatment of non-muscle invasive BCG unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.09.017_bib0022","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"issue":"16","key":"10.1016\/j.urolonc.2020.09.017_bib0023","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0024","article-title":"Intravesical gemcitabine for high-risk non-muscle-invasive bladder cancer after bacillus Calmette-Gu\u00e9rin treatment failure","author":"Sternberg","year":"2013","journal-title":"The Journal of Urology\u00ae"},{"key":"10.1016\/j.urolonc.2020.09.017_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Gu\u00e9rin","author":"Li","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.09.017_bib0026","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.017_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bju.14525","article-title":"OXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer","volume":"123","author":"Breyer","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2020.09.017_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12894-019-0497-x","article-title":"RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy","volume":"19","author":"Yang","year":"2019","journal-title":"BMC Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.09.017_bib0029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bju.14047","article-title":"Impact of bladder cancer on health-related quality of life","volume":"121","author":"Smith","year":"2018","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:01Z","timestamp":1761042061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920304397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1078143920304397"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non\u2013muscle-invasive bladder cancer after BCG failure","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}